Scancell Holdings (LON:SCLP) , the cancer vaccine developer, announced that its collaboration with ImmuneRegen BioSciences (announced in June 2010) is already bearing some fruit. The companies have tested an ImmunoBody based DNA vaccine in combination with ImmuneRegen's Homspera vaccine adjuvant technology in an animal model. The results of this test indicate that Homspera increased the immune response over that of the DNA vaccine alone. Scancell's first ImmunoBody vaccine candidate, SCIB1 for melanoma, is currently in Phase I clinical trials in the UK. The Homspera compound was previously shown to increase the immune response of another potential melanoma (TRP-2 encoding) DNA vaccine. The ultimate aim of the collaboration between Scancell and ImmuneRegen is to develop a next generation melanoma vaccine therapy. The company also announced that it has appointed Matrix Corporate Capital LLP as joint broker along with Zeus Capital.
The SCLP share price has increased by 96% over the last year. Scancell Holdings Plc is currently graded c by LCF Research.
